You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable Hepatocellular Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable Hepatocellular Carcinoma Trial in Nanjing (Yttrium-90 carbon microspheres SIRT)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Yttrium-90 carbon microspheres SIRT
  • Nanjing, China
    Gao-Jun Teng
Jul 20, 2023

Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Taoyuan City, Taiwan
    Chang Gung Memorial Hospital at Linkou
Nov 17, 2023

Hepatocellular Carcinoma Trial (Atezolizumab, Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Oct 18, 2023

Adebrelimab, Hepatocellular Carcinoma, Transformation Trial in Xiamen (TACE with adebrelimab and bevacizumab)

Not yet recruiting
  • Adebrelimab
  • +4 more
  • TACE with adebrelimab and bevacizumab
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Jul 25, 2023

Hepatocellular Carcinoma Trial in Shanghai (Cadonilimab+TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Shanghai, Shanghai, China
    Eastern hepatobilliary surgery hospital
Jun 21, 2023

Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))

Not yet recruiting
  • Hepatocellular Carcinoma (HCC)
  • (no location specified)
Sep 11, 2023

Patterns of Transcatheter Arterial Chemoembolization Combined

Not yet recruiting
  • HCC
  • (no location specified)
Aug 29, 2023

Hepatocellular Carcinoma Trial in Taoyuan (ADI-PEG20)

Recruiting
  • Hepatocellular Carcinoma
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou branch
Sep 6, 2023

Unresectable Hepatocellular Carcinoma Trial in Changsha (Donafenib Tosilate Tablets, Toripalimab Injection)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Donafenib Tosilate Tablets
  • Toripalimab Injection
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Nov 28, 2022

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
May 16, 2023

Hepatocellular Carcinoma Trial in Shanghai (M-TACE)

Enrolling by invitation
  • Hepatocellular Carcinoma
  • M-TACE
  • Shanghai, Shanghai, China
    Department of Interventional Radiology, Zhongshan Hospital, Fuda
May 24, 2023

Tislelizumab, Lenvatinib, TACE Trial in Nanning (Tislelizumab and Lenvatinib)

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Tislelizumab and Lenvatinib
  • Nanning, Guangxi, China
    The Affiliated Cancer Hospital of Guangxi Medical University
Jan 25, 2023

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Cadonilimab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
Apr 7, 2023

Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors Trial in Nanning (Cadonilimab,

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • +2 more
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Sep 13, 2023

Unresectable Hepatocellular Carcinoma (HCC) Trial in Milano, Rozzano, Barcelona (NMS-01940153E)

Recruiting
  • Unresectable Hepatocellular Carcinoma (HCC)
  • Milano, Italy
  • +2 more
Dec 2, 2022

Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
    • (no location specified)
    Dec 19, 2022

    Hepatocellular Carcinoma Non-resectable Trial in Belgium, Germany, Italy (BioPearl™)

    Not yet recruiting
    • Hepatocellular Carcinoma Non-resectable
    • BioPearl™
    • Brussels, Belgium
    • +5 more
    Jun 20, 2023

    Unresectable Hepatocellular Carcinoma, Oligometastatic Disease Trial in Beijing (SBRT plus tislelizumab and regorafenib)

    Recruiting
    • Unresectable Hepatocellular Carcinoma
    • Oligometastatic Disease
    • SBRT plus tislelizumab and regorafenib
    • Beijing, Beijing, China
      Peking University Cancer Hospital
    Jun 15, 2023

    Hepatocellular Carcinoma Trial (Ezurpimtrostat, Atezolizumab, Bevacizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Grenoble, France
      University Hospital
    Dec 23, 2022

    Hepatocellular Carcinoma Trial in Brussels (Radioembolization using Holmium-166)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Radioembolization using Holmium-166
    • Brussels, Anderlecht, Belgium
      Hôpital Universitaire Erasme, ULB
    Dec 7, 2022

    Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma

    Completed
    • Stage III Hepatocellular Carcinoma AJCC v8
    • +6 more
    • Yttrium Y 90 Glass Microspheres
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 12, 2022

    Hepatocellular Carcinoma Trial in Guangzhou (TACE-HACI, plus atezolizumab-bevacizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • TACE-HACI, plus atezolizumab-bevacizumab
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Feb 20, 2023

    Hepatocellular Carcinoma, Cancer of Liver Trial (PXS-5505 and Atezolizumab and Bevacizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Cancer of Liver
    • PXS-5505 and Atezolizumab and Bevacizumab
    • Rochester, New York
      University of Rochester
    Nov 3, 2022

    Camrelizumab Combined With Apatinib Mesylate in Unresectable

    Recruiting
    • Hepatocellular Carcinoma
      • Fuzhou, Fujian, China
        Mengchao Hepatobiliary Hospital, Fujian Medical University
      Aug 24, 2022

      Hepatocellular Carcinoma Trial in New York (SBRT, TACE)

      Completed
      • Hepatocellular Carcinoma
      • New York, New York
        Icahn School of Medicine at Mount Sinai
      Nov 22, 2022